Stopped: This study was terminated prior to its planned completion due to unexpected low participant inclusion.
The goal of this clinical trial is to compare the quality of mesoangioblasts isolated from various patient groups suffering from muscle atrophy. This study includes cancer cachexia and muscle-impaired elderly and a control group of the same age. The quality will be defined on these following outcomes: * The number and distribution of the mesoangioblasts in a muscle biopsy to define if there are sufficient mesoangioblasts to start a culture. * The proliferation capacity to define if we can culture them the numbers required for systemic treatment. * The myogenic capacity to define if the mesoangioblasts are sufficiently capable to generate muscle fibres. Participants will: * Undergo a muscle biopsy (needle biopsy or rest material from surgery, \~50mg) * Donate blood (\~20 ml) * Fill in SARC-F questionnaire (evaluate sarcopenia score) * Fill in SQUASH questionnaire (evaluate physical activity of previous week) Researchers will compare groups (muscle-impaired elderly vs control; cancer cachexia vs control) to see if there is a difference regarding quality. These results will define the potential of autologous mesoangioblast therapy within these groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of mesoangioblasts ex vivo isolated from muscle biopsy
Timeframe: 1 day
Proliferation capacity of mesoangioblasts in vitro
Timeframe: 1 day
Myogenic capacity of mesoangioblasts in vitro
Timeframe: 1 day
Distribution of mesoangioblasts in a muscle biopsy
Timeframe: 1 day